deaths (OS)

metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 1.0better0.35.0100 %
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 1.0better0.35.0100 %
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 1.0better0.35.0100 %
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 1.0better0.35.0100 %
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 1.0better0.35.099 %
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 1.0better0.35.0100 %